Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
Vancouver, BC – January 4, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, and Alan Kozikowski, PhD, Chief Scientific Officer, will present…
